Eli Lilly and Company (LLY) Expected to Announce Quarterly Earnings on Thursday

Eli Lilly and Company (NYSE:LLY) is expected to announce its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of $6.42 per share and revenue of $16.0946 billion for the quarter. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS.Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 10:00 AM ET.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the firm earned $3.92 earnings per share. The company’s revenue for the quarter was up 37.6% compared to the same quarter last year. On average, analysts expect Eli Lilly and Company to post $23 EPS for the current fiscal year and $31 EPS for the next fiscal year.

Eli Lilly and Company Stock Up 1.6%

Shares of NYSE LLY opened at $812.33 on Thursday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $935.63. The company has a market capitalization of $768.84 billion, a PE ratio of 53.09, a price-to-earnings-growth ratio of 1.14 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm’s 50-day moving average is $762.81 and its two-hundred day moving average is $766.75.

Analysts Set New Price Targets

Several analysts have issued reports on LLY shares. The Goldman Sachs Group upped their price target on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a report on Friday, October 10th. Leerink Partners reaffirmed a “market perform” rating and issued a $715.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 7th. Cantor Fitzgerald set a $925.00 price target on shares of Eli Lilly and Company and gave the company an “overweight” rating in a report on Thursday, October 9th. Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Finally, Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $938.61.

Insider Activity

In related news, CEO David A. Ricks purchased 1,632 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gabrielle Sulzberger purchased 117 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock valued at $2,894,841 in the last ninety days. 0.13% of the stock is owned by company insiders.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently bought and sold shares of LLY. Raymond James Financial Inc. grew its stake in Eli Lilly and Company by 1.4% during the second quarter. Raymond James Financial Inc. now owns 1,491,877 shares of the company’s stock worth $1,162,962,000 after buying an additional 20,661 shares during the period. California State Teachers Retirement System boosted its stake in Eli Lilly and Company by 0.4% during the 2nd quarter. California State Teachers Retirement System now owns 1,264,371 shares of the company’s stock valued at $985,615,000 after acquiring an additional 4,951 shares during the last quarter. Lazard Asset Management LLC boosted its stake in Eli Lilly and Company by 30.5% during the 2nd quarter. Lazard Asset Management LLC now owns 1,017,898 shares of the company’s stock valued at $793,481,000 after acquiring an additional 238,005 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in Eli Lilly and Company by 1.0% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 772,667 shares of the company’s stock valued at $602,803,000 after acquiring an additional 7,812 shares during the last quarter. Finally, Holocene Advisors LP boosted its stake in Eli Lilly and Company by 25.5% during the 2nd quarter. Holocene Advisors LP now owns 679,699 shares of the company’s stock valued at $529,846,000 after acquiring an additional 138,107 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.